Announcements Trials
Browse Landscape

Phase

Phase 2 186Phase 3 85Phase 1 70Phase 1/2 58Phase 4 10Phase 2/3 5Phase NA 3Phase EARLY_PHASE1 3

Status

Recruiting 2Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 3Vitamin D Deficiency 1Smoldering Multiple Myeloma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Plasmacytoma 1POEMS Syndrome 1Neuroblastoma 1Neoplasms, Plasma Cell 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Leukemia-Lymphoma, Adult T-Cell 1Immunoblastic Lymphadenopathy 1

Interventions

Cyclophosphamide 6Dexamethasone 5fludarabine 4Bortezomib 468Ga-pentixafor 4Melphalan 3Lenalidomide 3Granulocyte Colony-Stimulating Factor 3Positron Emission Tomography Computed Tomography 2Fluorodeoxyglucose F18 2Filgrastim 2tocilizumab 1ruxolitinib 1pomalidomide 1methyl prednisolonate 1ioversol 1iberdomide 1fludarabine phosphate 1eltrombopag 1elotuzumab 1daratumumab 1carfilzomib 1blinatumomab 1Thalidomide 1Tacrolimus 1Simvastatin 1Prochlorperazine 1Pemetrexed 1Ondansetron 1Mycophenolic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Multiple Myeloma × Lenalidomide × Clear all
NCT05846880 2025-04-08

VitD3 Supplementation in Patients With Multiple Myeloma

Augusta University

Phase EARLY_PHASE1 Recruiting
100 enrolled
Plasma cell

Multiple Myeloma, Vitamin D Deficiency

NCT06209606 2024-12-17

Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma

Oncotherapeutics

Phase EARLY_PHASE1 Recruiting
30 enrolled
Plasma cell

Multiple Myeloma

NCT01537861 2015-01-26

Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma

Washington University School of Medicine

Phase EARLY_PHASE1 Terminated
7 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡